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When considering the role of improved pathological or
molecular markers in local therapy, their potential impact on
both treatment selection and its outcome must be taken into
account. At present, the selection of mastectomy or breast
conserving surgery (BCT), consisting of lumpectomy and
whole breast irradiation, for an individual patient is
determined by the extent of disease within the breast and
ability to tolerate radiotherapy [1]. In the absence of medical
contraindications, patient preference is the final determinant
of treatment choice.
How accurately the extent of disease is assessed with
currently available tools can be evaluated by examining
mastectomy rates in patients who are initially selected for
BCT and the use of re-excision to obtain negative margins in
patients undergoing BCT. The available data indicate that
disease too extensive to allow BCT is reliably identified with
clinical evaluation, diagnostic mammography and ultrasono-
graphy. Morrow and coworkers reported that only 2.9% of
263 patients selected for BCT between 1989 and 1993
required conversion to mastectomy [2]. In a population-based
study conducted in 800 patients from the Los Angeles and
Detroit Surveillance, Epidemiology and End Results Registry
(SEER) treated between June 2005 and May 2006, 12% of
patients were converted from BCT to mastectomy [3].
However, in 8% this conversion took place after a single
lumpectomy attempt, suggesting that re-excision would have
allowed successful BCT in some of these cases. In contrast
to the low rate of conversion from BCT to mastectomy, re-
excision to obtain negative margins is a common surgical
procedure. In the population-based study 22% of patients
required re-excision [3], and in some studies the rate of re-
excision approaches 50% [4]. These findings suggest that a
more precise definition of microscopic extent of disease with
molecular tools would facilitate surgical excision. Although
this idea is attractive, it is associated with major pitfalls,
illustrated by experience with magnetic resonance imaging
(MRI) of the breast.
MRI is well documented to be a more sensitive method for
detecting cancer than mammography or ultrasound. A meta-
analysis of 19 studies involving 2,763 breast cancer patients
revealed that MRI detected additional disease in 16% (range
6% to 34%) that led to more extensive surgical therapy [5]. It
has been assumed that these larger surgical procedures
were beneficial to the patient, but more recent studies have
cast doubt upon this assumption. Bleicher and coworkers
studied 290 patients with and without MRI and found no
significant difference in conversion from BCT to mastectomy
or in the likelihood of obtaining negative margins with a single
surgical excision [6]. In that study, as well as in a study from
the Mayo Clinic [7], the detection of additional foci of cancer
was found to increase the mastectomy rate significantly. The
MRI findings of additional disease are consistent with
observations from pathological studies that employed serial
subgross sections to examine the distribution of clinically
localized cancers within the breast and found evidence of
multifocality in as many as 63% of cases [8]. However,
extensive clinical experience has shown that these foci are
controlled with radiotherapy, and their incidence significantly
exceeds local recurrence rates in modern studies of BCT [9].
Although it is clear that the clinical importance of microscopic
multifocal disease is related to its volume, the threshold
volume that influences clinical outcome is unknown. The
indiscriminate application of molecular tools to detect this
disease runs the risk of unnecessarily increasing the
mastectomy rate without improving patient outcomes, as
illustrated by the MRI experience.
An important contribution of molecular and pathological tools
to selection of local therapy would be to identify tumour
phenotypes with a high risk of local recurrence after BCT,
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which would be best treated with initial mastectomy, or a
group at such low risk for local recurrence that radiotherapy
was not indicated. At present, the outcome of local therapy
appears to depend upon interactions between tumour
biology, disease burden and the therapy received. These are
clearly not independent variables, but the relative contribution
of each to outcome is poorly defined, making evaluation of
molecular predictors difficult. In a study conducted to
examine prediction of local recurrence with gene expression
profiling, Nuyten and colleagues [10] evaluated 10-year local
control rates as predicted by high and low scores on the
wound response profile, 70-gene profile, and the hypoxia
signature. Only the wound response profile was a significant
predictor of outcome (95% local recurrence free for low
score versus 71% for high score), and this was significant in
a multivariate analysis that adjusted for age, tumour size and
use of a boost dose of radiation. However, adjustments were
not made for margin status and the use of systemic therapy,
which are two of the most important clinical determinants of
local control.
In another study, Mamounas and coworkers [11] used the
21-gene recurrence score (Oncotype Dx™, Genomic
Healthcare, Inc., Redwood City, CA, USA) to examine local
control in patients receiving no systemic therapy, tamoxifen
alone, or tamoxifen plus chemotherapy. For each group, rates
of local recurrence were significantly higher for patients with
high risk scores than for those with low risk scores. The risk
for local recurrence was 18.4% in patients with high risk
scores receiving placebo, as compared with 7.8% in those
with high risk scores receiving chemotherapy and tamoxifen.
A high risk score indicates a high risk for systemic relapse
and need for adjuvant therapy. This study appears to provide
reassurance that a parallel benefit in reducing the risk for
local recurrence is seen, but that the recurrence score does
not identify a group with a risk for recurrence sufficiently high
to warrant mastectomy.
Nguyen and coworkers [12] used oestrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth
factor receptor (HER)-2 as surrogates for breast cancer
subtypes to examine the 5-year risk for local recurrence after
treatment with BCT. Local recurrence rates were 0.8% in
those with ER-positive and/or PR-positive, HER-2-negative
tumours (luminal A); 1.5% for ER-positive and/or PR-positive,
HER-2-positive patients (luminal B); 8.4% for hormone
receptor negative, HER-2-positive patients treated without
trastuzumab; and 7.1% for ER-negative, PR-negative and
HER-2 negative (basal) patients. This study indicates that
patients with hormone receptor positive tumours treated with
appropriate endocrine therapy have extremely low rates of
local recurrence. It is likely that similar results will be seen for
HER-2-positive patients treated with adjuvant trastuzumab,
because the randomized trials of adjuvant trastuzumab
revealed an approximately 50% reduction in locoregional
recurrence with trastuzumab treatment compared with
treatment with chemotherapy alone [13]. In addition, a similar
study examining locoregional recurrence after mastectomy
with and without radiotherapy by tumour subtype in patients
treated in the Danish Breast Cancer Group trials found that
the lowest rates of local recurrence were seen in the ER-
positive and/or PR-positive group who received radiotherapy,
regardless of HER-2 status [14]. The risk for chest wall
recurrence with radiotherapy was higher in the HER-2 group
(without trastuzumab) and in the triple negative group, which
is the same finding as seen in patients treated with BCT [12],
and indicates that although these markers may be prognostic
they are not predictive of benefit from a particular type of
local therapy.
In summary, to date, pathological or molecular markers that
identify a subgroup of patients who are at sufficiently high risk
for local recurrence after BCT to justify mastectomy have not
been identified. The availability of targeted systemic therapy
has a major impact on risk for local recurrence, and
differences in local recurrence rates on the basis of ER, PR
and  HER-2 are present in patients treated with both
mastectomy and BCT. The available information on molecular
phenotypes and risk for local recurrence may be used to
refine estimates of the benefit of treatment in controversial
areas, such as the use of postmastectomy radiotherapy in
patients with one to three involved nodes, the use of a boost
dose of radiotherapy in postmenopausal women, or in
assessing the adequacy of surgical resection.
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